AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Crossject

CR
Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things get going
Target
Upside 197%
Price (€) 3.9
Market Cap (€M) 142
Perf. 1W: -5.11%
Perf. 1M: -24.9%
Perf. 3M: -9.93%
Perf Ytd: -21.5%
10 day relative perf. to stoxx600: -23.8%
20 day relative perf. to stoxx600: -31.4%
Financing issue 06/04/2017

The capital increase was successful

Fact

The capital increase was 137% subscribed, raising the group equity by some €4.98m gross after the exercise of the 15% extension clause.


Analysis

As a reminder, the capital increase was carried out from 16 to 30 March at €4.5 per share. As a result of this successful operation, the number of shares will rise by 1.107m (to be listed as of 7 April) to 8,813m. The company will also have enough cash to finance the next two financial years, even before partnerships and tax credits (CIR).


Impact

We will fine-tune our numbers, based on the outcome of the capital increase, but this will only be marginal since we have already taken into account this new issue.


Updates

25 Sep 17 Earnings/sales releases
H1 17: a new NTE in the pipeline...and further d...

06 Apr 17 Financing issue
The capital increase was successful

13 Mar 17 Earnings/sales releases
FY16 results - untelling (as expected) and a €4....

20 Sep 16 Earnings/sales releases
H1 16 results: not very telling as expected

29 Aug 16 Other news/comments
When apparent threats are also opportunities

25 Feb 16 Initiation cov.
Initiating coverage of Crossject.

.